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Results: 
842-2 Accumulation of a Novel Macrophage-Targeting 
Photodynamic Compound Within Lipid-Rich 
Atherosclerotic Plaques 
Ahmed Tawekol, Alan Fischman, Tayyaba Hasan, Touqir Zahra, James Muller, Michael 
Hamblin, Massachusetts General Hospital, Boston, Massachusetts. 
Vulnerable atherosclerotic plaques contain an abundance of inflammatory cells. We 
recently developed a photodynamic therapeutic (PDT) agent, (chlorin e8 conjugated with 
maleylatad albumin), that is recognized by scavenger receptors and can target macroph- 
ages with high selectivity. We therefore sought to test the hypothesis that the novel mac- 
rophage-targeting photodynamic compound accumulates in experimental atherosclerotic 
lesions in quantities that are sufficient for photodynamic therapy. 
Four New Zealand rabbits were studied, in which atherosclerotic lesions were induced in 
2 by de-endothelialization of the infradiaphragmatic aorta followed by a 6% peanut oil-2% 
cholesterol diet for 10 weeks. Thereafter chlorine6 conjugated with maleylated albumin 
was administered intravenously to the animals. At 24 hours after injection of the PDT 
compound, the animals were sacrificed, and the aortas examined for uptake of the fluo- 
rescent PDT agent. 
PDT uptake was significantly higher within the atherosclerotic aortas (5.2 +/- 3.2 vs. 1.9 
+/- 1.2, ca6 fluorescence units/gm tissue x 10 6 atherosclerotic aorta vs control aorta, 
p<0.03, n=8 segments). 
These data indicate that this macrophage-targeted photodynamic ompound accumu- 
lates in atherosclerotic plaques, and support future efforts to employ PDT compounds to 
ablate inflammatory foci within atherosclerotic plaques. 
9:00 a.m. 
842-3 Stat in Admin is t ra t ion  in Pat ients  With Acute  Coronary  
Syndromes: Results in Decreased Heat Release of  
Culprit Atherosclerotic Lesions 
Christodoulos Stefanadis. Konstantinos Toutouzas, Elefthedos Tsiamis, Ioannis 
Kallikazaros, Manolis Vavouranakis, Sophia Vaina, Athanasios Trikas, Christina 
Chrysochoou, Dimos Panagiotakos, PavIos Toutouzas, Hippokration Hospital, Athens, 
Greece. 
Background: It has been shown, that there is thermal heterogeneity within human ath- 
eroscterotic plaques. Recent studies have suggested, that statins may induce mechani- 
cal plaque stability by reduction of inflammatory cells within the plaque. This study was 
designed to examine the effect of statins on atherosclerotic plaque stabilization by mea- 
suring the temperature of atherosclerotic plaques. Methods: We studied 60 patients 
(pts), 36 pts with unstable angina (UA) and 24 pts with acute myocardial infarction (AMI). 
All pts underwent diagnostic catheterization. Thirty-two pts (18 pts with UA and 14 pts 
with AMI) were under statin treatment for over a month and 28 pts were not receiving 
statins (18 pts with UA and 10 pts with AMI). Fifty-five pts were under aspirin treatment. 
Total cholesterol and low-density cholesterol were measured in all pts. A thermography 
catheter previously validated (Medispes S.W.A.G.zug-Switzerland) was used during the 
diagnostic catheterization, in order to measure the temperature difference (TD) between 
the atherosclerotic plaque and the healthy vessel wall. Results: TD was progressively 
increased in pts with UA compared to pts with AMI (0.41 ± 0.28 vs 0.68 ± 0.41°C, p < 
0.02). When we categorized the study population into pts receiving statins and pts not 
treated with statins, TD was lower in the treated group (0.41 ± 0.4 vs 0.85 ± 0.3°C, p < 
0.01). Moreover, untreated pts with UA or AMI had greater TD compared to treated pts 
(UA: 0.45 ± 0.26 vs 0.29 ± 0.25°C, p < 0.02; AMI: 0.82 ± 0.51 vs 0.56 ± 0.34 ° C, p < 
0.01). Multivariate analysis showed that treatment with statins was an independent factor 
in the assessment of temperature variation, adjusted for age, hypercholesterolemia, 
hypertension, smoking, aspirin intake, and clinical syodrome.Conclusions: Pts with 
unstable plaques, under stalin tretment have decreased heat production from the culprit 
lesion Thus, statins may exert a direct antinflammatory effect in the atherosclerotic 
plaque beyond their effects on plasma lipids. 
9:15 a.m. 
842-4 Association Between Ischemic Electrocardiographic 
Abnormalities and C-Reactive Protein in a General 
Population 
Folkert W. Asselberos, Ad J. van Boven, Gilles F. Diercks, Hans H. Hillege, Erik M. 
Stuveling, Jan A. Kors, Wiek H. van Gilst, University of Groningen, Groningen, The 
Netherlands, Academic Hospital Groningen, Groningen, The Netherlands. 
Background: The inflammatory marker C-Reactive protein (CRP) and ischemic electro- 
cardiographic (ECG) abnormalities reflects both vascular instability and are easy to 
obtain risk factors for fatal and nonfatal cardiac events. Their association however, has 
never been studied in a general population. Our objective was to test the hypothesis that 
there is an association between the level of CRP and the presence of electrocardio- 
graphic abnormalities. 
Methods: Minnesota coded electrocardiograms were used to determine ischemic elec- 
trocardiographic abnormalities in 8501 subjects (aged 28 to 75, 49.8% male) from the 
PREVEND study, a population-based screenings programme in which subjects were 
stratified for the presence of an increased level of urinary albumin excretion. High sensi- 
tive CRP was measured by nephelometry (BN II, Dade Behring, Marburg, Germany). 
Abnormal T-axis was defined as -180 to -15 and 105 to 180 degrees. CRP levels were 
divided below and above the upper quartile (CRP>2.60 mg/dl). 
Prevalence of ECG abnormalities, Odds Ratio (95% CI) 
Ischemic Infarct patterns Abnormal T-axis 
abnormalities 
Elevated CRP 1 1.56 (1.30-1.87)* 1.71 (1.32-2.22)* 3.18 (2,12-4.77)* 
Elevated CRP 2 1.39 (1.15-1.67)* 1.58 (1.21-2.01)* 2.64 (1.75-3.99)* 
Elevated CRP 3 1.24 (0.99-1.55) 1.34 (0.97-1.85) 2.18 (1.27-3.76)** 
*p<0.001 ,**p<0.01 
1 unadjusted 
2adjustad for age and gender 
3adjusted for age,geoder, hypercholestarelemia,diabetes, moking,family history for 
atherosclerose and body mass index>27kg/m2 
Conclusion: These results suggest that in a large general population, elevated CRP is 
associated with ECG abnormalities, suggestive for cardiac ischemia. Therefore, CRP may 
be useful in early risk profiling to improve cardiovascular isk assessment and treatment. 
9:30 a.m. 
842-5 Does Extent of Pretreatment Atherosclerosis Influence 
the Effects of Conjugated Equine Estrogens on 
Atherosclerosis Progression? 
Mary S. Anthony. Thomas B. Clarkson, Wake Forest University School of Medicine, 
Winston-Salem, North Carolina. 
Background: Recent clinical trial data suggest no beneficial effects of hormone replace- 
ment therapy (HRT) on coronary artery atherosclerosis progression in women with angio- 
graphically verified lumen stenosis. However, considerable observational and nonhuman 
primate data indicate that HRT inhibits progression of atherosclerosis in its early stages. 
Consequently, whether HRT has a differential effect on atherosclerosis progression 
depending on extent of preexisting atherosclerosis becomes importanL 
Methods: Cynomolgus monkeys were fed a moderately atherogenic diet for two years to 
induce atherosclerosis, after which a biopsy of the iliac artery was taken to quantify pre- 
treatment atherosclerosis (measured as intimal area [IA] averaged across three sections) 
and all animals were ovariectomized to induce surgical menopause. For the 3-yasr post- 
menopausal pedod, they were randomized to no treatment (Control, n=56) or conjugated 
equine estrogens (CEE, n=62) at a dose comparable to a dose for women of 0.825 rag/day 
and the atherogenic diet was continued. At the end of the study atherosclerosis was quan- 
tified in the contralataral lilac artery. For this analysis, individuals were divided into tertiles 
based on baseline IA. 
Results: Overall the CEE group had less atherosclerosis than the control group (p=0.002). 
As expected, IA at the end of the study was higher in the tertiles with more atherosclerosis 
at baseline (p for treod--O.0001). There were different effects of CEE depending on the 
amount of preexisting atherosclerosis (significant reatment by tertile interaction [p=0.01]). 
The nature of this interaction was that with increasing baseline atherosclerosis, there was 
less of a difference between the CEE and Control groups in outcome atherosclerosis, in 
the lowest tertile, IA at outcome was 0.30 mm 2 smaller in the CEE group compared to Con- 
trols (p=0.0001); in the middle tertile the CEE group IA was 0.15 mm 2 smalier (p=0.33) and 
in the highest terti~e IA was only 0.09 mm 2 smaller (p=0.71) in the CEE group. 
Conclusions: These data suggest that CEE might be less effective at inhibiting athero- 
sclerosis progression when pretreatment atherosclerosis is more advanced. 
9:45 a.m. 
842-6 PPAR ~hAgoniet Induces Regression of Atherosclerotic 
Plaques: In Vivo Study by High Resolution Magnetic 
Resonance Imaging 
Roberto CortL Julio L Osende, Valentin Fustsr, Samuel D. Wright*, Zahi A. Fayad, Elisha 
Dickstain, John T. Fallon, Juan J. Badimon, Cardiovascular Institute Mount Sinai School 
of Medicine, New York, New York, *Merck Research Laboratories, New Jerse~ 
Introduction Nuclear receptor PPAR- 7 regulates adipogenasis and lipid metabolism. It is 
expressed in macrophages and may have antiatherogenic effects. We reported the abil- 
ity of MRI to monitor in vivo changes in atherosclerotic (AT) lesions. Our objective was to 
compare the effects of simvsstatin, a PPAR~-agonist (2-(2-(4-phenoxy-2-propy- 
Iphoxy)ethyl)indole-5-acetic acid) and their combination on pre-established lesions in a 
rabbit model using MRI and histology. 
Methods Aortic AT lesions were induced in rabbits by double balloon-injury and athero- 
genic diet. Following lesion induction,animals were MRimaged and, based on severity of 
the established AT lesion, assigned to the different groups: Progression (no therapy, 
n=5), simvastatin (5mg/kg/day, n=6), PPAR~agonist (5mg/Kg/day, n=5) and their combi- 
nation (n=7). The atherogenic diet was maintained during the study. After 6 months of 
treatment all rabbits were MR imaged, sacrificed and processed for histology. The effect 
of the treatments on AT lesions was assessed by measuring vessel wall area (VWA), a 
surrogate of AT burden. VWA measurements by MRI were normalized to the randomiza- 
tion value (each rabbit served as its own control). 
Results Good agreement between MRI and histopatology measurements of VWA was 
found(p<0.001, R=0.88). The mean VWA at the time of randomization was 8.4±0,6 mm2 
and did not differ between groups. The progression group showed a significant increase 
(21%; p<0.01) in VWA. All treatments significantly regressed the established AT lesions. 
The major therapeutic effect was observed in the simvastatin+PPAR y group with a 14% 
reduction, while the simvaststin and the PPAR 7 groups had a 9.5% and 5% inhibition 
respectively.The composition and characteristics of the plaques are being analysed. 
Conclusion MRI documents serial changes in AT lesions in response to therapeutic 
interventions. We report striking effects on AT lesion regression by combining two mech- 
